



ORIGINAL RESEARCH PAPER

Medicine

A STUDY OF CLINICAL & ETIOLOGICAL PROFILE OF EXUDATIVE PLEURAL EFFUSION

KEY WORDS: Pleural Effusion, Tuberculosis, Malignancy.

Dr. Vasireddy Aruna.M.D*

Asst. professor, Dept. of Pulmonary medicine, SMC, Vijayawada. Affiliated to Dr. NTR University of Health sciences, VIJAYAWADA. *Corresponding Author

Dr. Sabinkar Babu Lal.M.D

Professor and HOD, Dept. of Pulmonary medicine, SMC, Vijayawada Affiliated to Dr. NTR University of Health sciences, VIJAYAWADA.

Dr. S. Sessa Sai.M.D

Junior resident, Dept. of Pulmonary medicine, SMC, Vijayawada Affiliated to Dr. NTR University of Health sciences, VIJAYAWADA.

Dr. Ashish Devalkar.T.M.D

Junior resident, Dept. of Pulmonary medicine, SMC, Vijayawada Affiliated to Dr. NTR University of Health sciences, VIJAYAWADA.

ABSTRACT

BACKGROUND: Exudative pleural effusions are a common diagnostic problem in clinical practice, as the list of causes is quite exhaustive, although sometimes they can be inferred from the clinical picture. In the West the most common cause is Parapneumonic effusions followed by malignancy, while in India it is tubercular effusion followed by malignant effusion. Despite the availability of various tests, there is a need for defining the best diagnostic and cost effective approach to quickly diagnose and treat exudative pleural effusions

OBJECTIVES: To conduct a clinical & etiological study of exudative pleural effusion. To evaluate biochemical profile, cytological profile and radiological profiles of exudative pleural effusion.

METHODOLOGY: Prospective study of 100 patients with exudative pleural effusions attending Department of pulmonary medicine, Government general hospital, Siddhartha medical college, Vijayawada from February 2017 to January 2018.

RESULTS: There were 67 males and 33 females. The mean age was 41.6±15.74. The majority were tubercular in origin (67%), 13%, 8%, 3% and 6% were malignant effusions, Synpneumonic effusion, pancreatic effusions and empyema respectively. Diagnosis was not established in 3% of effusions. Massive effusions were seen in 53.8% of malignant effusions and 33.3% of empyemas. Most effusions had a total cell count between 1000 to 5000 cells /mm³. Lymphocyte predominant effusions were seen in 84.6% and 89.6% of malignant and tubercular effusions. 61.5% of malignant effusions had a positive cytology. Tubercular effusion had a pleural fluid ADA more than 40 IU/L. 92.3% of malignant effusion had pleural fluid ADA less than 30IU.

CONCLUSION : Pleural effusion is a commonly encountered in medical practice and in our country, the commonest cause is tuberculosis, as is evidenced from the present study. The initial step in evaluating case of pleural effusion is to establish the cause of pleural effusion which is done by a detailed history, clinical examination and investigations like a chest radiology and pleural fluid analysis. Even in the advanced diagnostic approaches, still detailed clinical history and examination of the patient is important to make a clinical diagnosis. All suspected cases of pleural effusion should undergo Sonography of the thorax along with routine chest x-ray. Fluid cytology should be done to confirm tuberculosis or to rule out malignancy, which guides the physician for further evaluation of the patient if required.

INTRODUCTION

Exudative pleural effusions are a common diagnostic problem in clinical practice, as the list of cause's is quite exhaustive,^[1] although sometimes they can be inferred from the clinical picture. The etiological distribution of pleural effusions in various series depends on the geographical area, patient's age, and advances in the diagnostic methods and treatment of the underlying causes. The difficulty in determining the cause of pleural effusion is shown by the fact that in many series "unknown etiology" constitutes nearly 15%.^[2] Exudative effusions require to be separated into infectious causes, noninfectious causes and malignancy. The most common causes in most series are infections and malignancy. In the West the most common cause is parapneumonic effusions followed by malignancy,^[1] while in India it is tubercular effusion followed by malignant effusion^[3] and a very few due to parapneumonic effusion.

India has the highest prevalence of tuberculosis in the world with 2/3rds of all TB patients being in India.^[4] Tuberculosis is the most common cause of effusion in India when compared to the West where malignancy and parapneumonic effusions are more common.^[5] Pleural tuberculosis is second in frequency after TB lymphadenitis.^[3] The clinical, biochemical and cytological parameters of tubercular effusion are shared by malignancy, both being exudates and predominantly lymphocytic effusions. This can pose a significant diagnostic dilemma. Adenosine deaminase enzyme activity, gamma interferon, polymerase chain reaction, lysozyme measurement pleural fluid tuberculous protein antibodies and various tumor markers like CA15-3, squamous cell

carcinoma antigen, etc. have been used to differentiate TB from non TB5. Other diagnostic tests including flow cytometry, chromosomal analysis of malignant cells, LDH isoenzymes assay, and tumor marker assays, immunohistochemical tests, and carcino embryonic antigen (CEA), are used to differentiate between benign and malignant effusions.^[5] Despite the availability of all tests, it might be necessary to avail of more invasive diagnostic tools like pleural biopsy or thoracoscopy to establish a diagnosis. Adenosine deaminase although shown to be promising in the West to differentiate tubercular from non tubercular effusion, in Asian countries was not found to be of much diagnostic value and has shown mixed results.^[6,7] There is hence a need for defining the best diagnostic and cost effective approach to quickly diagnose exudative pleural effusions.

MATERIALS AND METHODS

STUDY DESIGN

This is prospective study of 100 patients with exudative pleural effusions attending Department of pulmonary medicine, Government general hospital, Siddhartha medical college, Vijayawada from February 2017 to January 2018. A detailed clinical history and general physical examination was done on all the patients. A chest radiograph postero anterior view was done and the size of the effusion was estimated. The following investigations were done :Routine base line investigations like complete hemogram, ESR, LFT/RFT, Sputum for AFB, Sputum for CBNAAT, Chest X-ray – P/A view, USG Chest, diagnostic pleurocentesis was performed on all patients after taking informed consent and pleural fluid sent for these investigations: Biochemical

Study:Protein,Sugar,Chloride,LDH,ADA,Cholesterol;Cytological Study : Cell type,Cell count,Smear for malignant cells;Microbiological Study:Gram stain ,AFB,Culture and sensitivity.CT Chest and Pleural biopsy done whenever appropriate.

INCLUSION CRITERIA:

1. Both male and female patients with age more than 18 years admitted to chest ward, Government General Hospital presenting with features of pleural effusion.
2. Patients with exudative pleural effusion.

EXCLUSION CRITERIA :

1. Patients with other serious co-morbid conditions and those who are not able to co-operate for the study.
2. Patients who are found to have transudative pleural effusion after initial screening.
3. Patients who are immunocompromised (HIV Positive, long term usage of immunosuppressant drugs , steroids).positive patients less than 18 years of age.

STATISTICAL METHODS

The demographic data was expressed as mean +/- standard deviation. Comparison between groups was done by Chi-Square test and Fischer exact test for categorical variables and Kruskal-Wallis and Mann-Whitney tests for continuous variables.

RESULTS

One hundred patients with pleural effusions were studied from February 2017 to January 2018. There were 67 males and 33 females. The mean age was 41.6±15.74. The mean age among men was 41.25±15.25 and in women was 41.85±15.39,as shown in (table1). Majority of the patients were in the age group of 21-40 years and 41-60 years. The male to female ratio was 2:1,as depicted in (figure 1). In this study we classified patients as tubercular effusion in patients who were sputum positive for AFB or who had demonstrated acid fast bacilli in the pleural fluid or those who had a lymphocyte predominant effusion therapeutic response to tuberculosis. As shown in (figure 2),the majority were tubercular in origin (67%). There were 13% malignant effusions. Synpneumonic effusion and empyema were seen in 8% and 6% of patients respectively. Others causes included 3% of pancreatic effusions. Diagnosis was not established in 3% of effusions. Patients with tubercular effusion were much younger than those with malignant effusions (mean age 36.54+/-12.91 Vs 52.43+/-13.49) as shown in (table 2). All pancreatic effusions were seen in males (4.5%). Tubercular effusions more common among both females (72.7%) and males (64.2%) whereas Empyemas were seen in both sexes in equal percentages (6%),as depicted in (figure 3). As shown in (table 3),patients with tubercular effusion presented with fever as the predominant symptom (66.7%) followed by cough (56.7%) and breathlessness (43.3%). In those with malignant effusion it was breathlessness (61.5%) followed by cough (46.2%). In Synpneumonic effusion fever (100%) and cough (50%) were the major symptoms. All pancreatic effusions were present on left side. Tubercular, Malignant, Synpneumonic effusions and empyemas were more common on right side,as shown in (figure 4). Massive effusions (defined as pleural effusion occupying greater than 2/3rds of hemithorax on chest X-ray) were seen in 53.8% of malignant effusions and 33.3% of empyemas whereas moderate effusions are common in tubercular effusions (55.2%) as shown in (table 4). In all other causes they were more commonly mild to moderate in size. As depicted in (figure 5),majority of the effusions were straw colored (81%). Hemorrhagic effusions were seen commonly in pancreatic (66.7%) and malignant pleural effusions (53.8%). Most effusions had a total cell count between 1000 to 5000 cells /mm³,as shown in (table 5). Counts greater than 10,000/mm³ were seen predominantly in empyema (50%). Tuberculosis and malignancy were less commonly associated with high total leukocyte counts. 60 effusions out of 67 effusions (89.6%) were lymphocyte predominant in tubercular effusions,as shown in (figure 6). Lymphocyte predominant effusions were seen in 84.6% of malignancy. Synpneumonic effusion and empyema were neutrophil predominant. All the effusions where the diagnosis was not established were lymphocyte predominant. The ratio of pleural

fluid LDH to serum LDH was in the range of 1.84 ± 0.71 in tubercular effusions. Patients with tubercular and malignant effusions had ratios greater than 2 in 46.2% and 38.4% of patients respectively, as shown in (figure 7). Pleural LDH to serum LDH ratio was greater than 2 in all of empyemas (100%).Empyemas had low glucose levels with mean of 49.17. All pancreatic effusions had high glucose levels with mean of 113. 25% of Synpneumonic effusion, 10% of Tubercular and 7 % of malignant effusion also had pleural fluid glucose less than 40mg/dais depicted in (figure 8). Pleural fluid cytology was performed in all the patients with exudative effusions. No abnormal cell or AFB was seen in any of the tubercular effusions. 61.5% of malignant effusions had a positive cytology, as shown in (figure 9). The yield increased with the number of samples examined, but the numbers were too small to draw a definite conclusion. Pleural fluid ADA was done in 94 patients out of whom 67 were tubercular effusion, 13 patients with malignancy and 3 unknown etiology and 8 patients with parapneumonic effusion, as shown in (table 6). 31 patients with tubercular effusion had a pleural fluid ADA more than 40 IU/L. 92.3% of malignant effusion had pleural fluid ADA less than 30IU. 20.5% of tuberculosis had ADA between 30 and 40 IU/L. In patients in whom the diagnosis was not established, the pleural fluid ADA was less than 30 IU/L. In 28 patients with tubercular effusion, ADA was more than 70 IU/L.

Table 1.AGE DISTRIBUTION WITH GENDER

Age	Female		Male	
	Frequency	Percent	Frequency	Percent
≤20	2	6.1	3	4.5
21-40	16	48.5	31	46.3
41-60	10	30.3	25	37.2
61-80	5	15.1	8	12.0
Total	33	100.0	67	100.0
Mean ± SD	41.85±15.39		41.25±15.25	

Figure 1. GENDER DISTRIBUTION




Figure 2. ETIOLOGY




Table 2.AGE AND ETIOLOGY

Age	Etiology						Total
	E1	E2	E3	E4	E5	E6	
≤20	4	0	0	1	0	0	5
	6.0%	0.0%	0.0%	16.7%	0.0%	0.0%	5.0%
21-40	36	0	6	4	1	0	47
	53.7%	0.0%	75.0%	66.7%	33.3%	0.0%	47.0%
41-60	21	6	2	1	2	3	35
	31.3%	46.2%	25.0%	16.7%	66.7%	100.0%	35.0%
61-80	6	7	0	0	0	0	13
	9.0%	53.8%	0.0%	0.0%	0.0%	0.0%	13.0%
Total	67	13	8	6	3	3	100
	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %
Chi-square=39.35		Df=15		P-value <0.01			

Figure 3.GENDER AND ETIOLOGY




Figure 4.SITE OF EFFUSION IN DIFFERENT ETIOLOGIES




Table 3.FREQUENCY OF SYMPTOMS WITH DIFFERENT ETIOLOGIES

Symptoms	Etiology						Total
	E1	E2	E3	E4	E5	E6	
Cough	38	6	4	4	3	3	58
	56.7%	46.2%	50.0%	66.7%	100.0%	100.0%	58.0%
Breathlessness	29	8	0	3	2	0	42
	43.3%	61.5%	0.0%	50.0%	66.7%	0.0%	42.0%
Fever	44	0	8	5	0	0	57
	66.7%	0.0%	100.0%	83.3%	0.0%	0.0%	58.2%
Weight loss	21	4	0	0	0	0	25
	31.3%	30.8%	0.0%	0.0%	0.0%	0.0%	25.0%
Loss of appetite	18	4	0	0	0	0	22
	26.9%	30.8%	0.0%	0.0%	0.0%	0.0%	22.0%
Chest pain	1	0	2	2	0	0	5
	1.5%	0.0%	25.0%	33.3%	0.0%	0.0%	5.0%
Hemoptysis	1	4	1	0	0	0	6
	1.5%	30.8%	12.5%	0.0%	0.0%	0.0%	6.0%
Chi-square = 131.82 Df=10 P-value <0.01							

E1-Tubercular; E2-Malignant; E3-Synpneumonic; E4-Empyema; E5-Pancreatic; E6-Undiagnosed

Table 4.SIZE OF EFFUSION WITH DIFFERENT ETIOLOGIES

Size	Etiology						Total
	E1	E2	E3	E4	E5	E6	
Massive	7	7	0	2	0	0	16
	10.4%	53.8%	0.0%	33.3%	0.0%	0.0%	16.0%
Moderate	37	3	1	2	2	1	46
	55.2%	23.1%	12.5%	33.3%	66.7%	33.3%	46.0%
Mild	23	3	7	2	1	2	38
	34.3%	23.1%	87.5%	33.3%	33.3%	66.7%	38.0%
Total	67	13	8	6	3	3	100
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Chi-square=28.42 Df=10 P-value <0.01							

E1-Tubercular; E2-Malignant; E3-Synpneumonic; E4-Empyema; E5-Pancreatic; E6-Undiagnosed

Figure 5.APEARANCE OF PLEURAL EFFUSION WITH DIFFERENT ETIOLOGIES





Table 5.ASSOCIATION OF TOTAL COUNTS WITH DIFFERENT ETIOLOGIES

Total count	Etiology						Total
	E1	E2	E3	E4	E5	E6	
<1000	8	2	1	0	1	1	13
	11.9%	15.4%	12.5%	0.0%	33.3%	33.3%	13.0%
1000-5000	44	8	3	1	0	2	58
	65.7%	61.5%	37.5%	16.7%	0.0%	66.7%	58.0%
5000-10000	14	1	2	2	1	0	20
	20.9%	7.7%	25.0%	33.3%	33.3%	0.0%	20.0%
>10000	1	2	2	3	1	0	9
	1.5%	15.4%	25.0%	50.0%	33.3%	0.0%	9.0%
Total	67	13	8	6	3	3	100
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Chi-square=30.66 Df=15 P-value <0.01							

E1-Tubercular; E2-Malignant; E3-Synpneumonic; E4-Empyema; E5-Pancreatic; E6-Undiagnosed

Figure 6.ASSOCIATION OF DIFFERENTIAL COUNTS WITH DIFFERENT ETIOLOGIES



E1-Tubercular; E2-Malignant; E3-Synpneumonic; E4-Empyema; E5-Pancreatic; E6-Undiagnosed

Figure 7.PLEURAL FLUID TO SERUM LDH RATIOS WITH DIFFERENT ETIOLOGIES




Figure 8.PLEURAL FLUID GLUCOSE AND ETIOLOGIES




Figure 9. PLEURAL FLUID CYTOLOGY IN MALIGNANT PLEURAL EFFUSION




Table 6. ASSOCIATION OF ADA WITH DIFFERENT ETIOLOGIES

ADA	Etiology						Total
	E1	E2	E3	E4	E5	E6	
<30	0	12	7	0	3	3	25
	0.0%	92.3%	87.5%	0.0%	100.0%	100.0%	36.8%
31-40	8	0	1	0	0	0	9
	20.5%	0.0%	12.5%	0.0%	0.0%	0.0%	13.2%
41-70	31	1	0	0	0	0	32
	79.5%	7.7%	0.0%	0.0%	0.0%	0.0%	50.0%
Total	39	13	8	0	3	3	66
	100.0%	100.0%	100.0%	0.0%	100.0%	100.0%	100.0%
Chi-square=61.89 Df=10 P-value <0.01							

DISCUSSION

This study was carried out in the Department of Pulmonary Medicine, Siddhartha Medical College, Vijayawada from February 2017 to January 2018. 100 patients with pleural effusion were studied of which 67 % were cases of tuberculous effusion and 33 % were cases of non tuberculous effusion. The present study is particularly relevant in our country, as it has a high prevalence of tuberculosis.

Etiology of Pleural Effusion

Out of the 100 cases of pleural effusion, which were studied, 67 cases were of tuberculous effusion. This was reflective of the high prevalence of tuberculosis in the area being studied. The remaining 33 cases were of malignant effusion (13 cases), synpneumonic effusion (8 cases) and 3 cases of empyema, 3 cases of pancreatic effusion, 3 cases of unknown etiology. In comparison, the distributions in some of the previous studies are: Prabhu desai^[9]- tubercular effusion comprises 64% of infective cause and 8% were of empyema. In patients of age more than 40 yrs, malignant effusion was more common; Al quatrain^[9]- common diagnose was tubercular (37%) followed by neoplasm (8%), parapneumonic (14%). KZ mamum^[10] also showed tubercular and malignancy were the major causes of pleural effusion.

Sex Distribution

There were a greater number of male patients than female patients in this study with 67 males and 33 females. In comparison, the sex distributions in some of the previous studies are : Subhakar.K^[11] – 77.5% males and 22.5% females; Leesly J. Burgess^[12] – 58% males and 42 % females; Al Quorian^[9] -Of 101 cases 45 were males and 56 females; Luis Valdes^[13] - 56.6% males and 43.3% females.

Age Distribution

The present study comprised of patients aged from 18 years to 80 years (mean age: 41.85+/-15.39 years). The mean age in case of tuberculous effusion was 39 years, with the maximum number of patients between 20 –60. The mean ages in case of malignant, synpneumonic effusions were 63 years, 33 years respectively. In comparison, the age distributions in some of the previous studies are: Lesley.J. Burgess^[12] - the ages of the patients ranged from 6 months to 98 years with a mean age of 49+/-20.72 years; Subhakar.K^[11] - the age of the patients ranged from 5 to 80 years with the mean ages in the various groups being: tuberculous 30.7+/-13.82 years, malignant 51.15+/-11.56 years and transudative effusion 48.15+/-6.92 years.

The patients with TB were younger than the patients with malignancy. Their mean age was 39 years, consistent with Luis Valdes et al (34 years)^[14] and S.K.Sharma et al (33 years)^[15]. Earlier studies done in United States by Epstein et al^[16] and Aho K et al.^[17] showed a mean age of 54 and 28 years respectively. Malignant effusions in this study were seen in older age group (64yrs). This is older than that reported by Sharma et al^[18] (mean age 47 years), but consistent with reports from the West (65 years)^[19]. Male to female ratio was 2:1 in this study. Majority of the patients were in the age group of 21- 40 years and 41 – 60 years irrespective of etiology.

Presenting complaints

The following were the presenting complaints among the patients, on admission. The commonest symptoms were cough (55%) and breathlessness (42%), followed by fever 57%, weight loss 25%, chest pain 6%, and hemoptysis 5%. Most of the patients with synpneumonic effusion, had complaints of a short duration with an acute onset, whereas those with tuberculous effusion and malignancy had complaints of a longer duration. In comparison to other studies: Follader^[20] – main complaints were fever (41/44), chest pain (41/44) and weight loss (34/44). These findings are also compatible with the studies done earlier by Moudgil et al^[21] and Berger H.W et al^[22]. Patients with malignant effusion had dyspnoea as a common symptom (61 %) similar to that seen in a study by Chernov B et al^[23] though cough (42%) was the other predominant symptom. Patients with synpneumonic effusion had clinical symptoms suggestive of pneumonic illness.

Clinical Findings

Out of the 100 patients with pleural effusion 61 patients had a right sided effusion and 35 patients had a left sided. 4 cases of empyema were on right side. In comparison to other studies: Al Quarain^[9] – pleural effusion was more common in right side (55%) than on the left (32%); In Follander^[20] – both right and left side effusion were of equal distribution.

Investigations

Sputum for AFB

In this study, out of the 67 cases of tuberculous effusion, in 7 cases acid fast bacilli could be demonstrated in the sputum by Ziehl Nielson's staining (16 %). The detection of AFB in the sputum in the tuberculous depends upon the associated lung parenchymal lesion. In comparison to other study: Subhakar. K^[11] - 7 of the 62 patients with tuberculous pleural effusion showed sputum positivity for AFB (i.e. 11%).

Radiology

Chest X-ray showed the presence of fluid in all the patients and was diagnostic of pleural effusion. 28 of the patients also had associated pulmonary lesions. In radiological estimation of pleural fluid volume – majority of tubercular (37 cases) had moderate effusion.(53.8%) cases of malignant effusion had massive effusion but synpneumonic mild effusion. Majority of malignant effusion had massive effusion and synpneumonic had minimal effusion. In our study we demonstrated that massive effusion was most commonly seen in malignant effusion group (53.8%) similar to that observed, by Maher et al (55%)^[24]. Large effusions were less commonly seen in the other observed etiologies. Although the majority of effusions were straw colored, hemorrhagic effusions were encountered predominantly in malignant effusions and pancreatic effusions. This is a well established fact.^[5] In Follander^[20] study of radiological had shown parenchymal lesions in 23% of cases. Bowen^[25] in his study in quantitative study of pleural effusion, divided pleural effusion into mild (250-600) and massive (>1500) pleural effusion.

Pleural Fluid Analysis:

1.Pleural fluid Cytology : The cell count in the pleural fluid ranged from 360 to 13000 cells/mm³. The average cell counts in tubercular, malignant, synpneumonic and empyema was 3814, 4618, 6093, and 5800 respectively. Polymorphonuclear leucocytes were predominately seen in synpneumonic effusions and lymphocytes were predominately seen in tuberculous effusion. Lymphocytes were also seen in the some of the cases of

malignant effusions. Malignant cells could be demonstrated in 8 (61.5 %) cases of malignant effusion. The majority of effusions had total leukocyte count from 1000 to 5,000 mm³. Understandably the majority of empyemas had cell counts greater than 10,000 mm³ (50%) consistent with Light's observation et al.^[26] 89.6 % of TB effusions and 84% of malignant effusions had lymphocyte predominance. Our result was similar to the study done by Valdes L et al^[19] where they have encountered neutrophil predominant tuberculous effusion in only 6.7% of patients and only one malignant effusion had neutrophil predominant effusion (3%). Among tubercular effusions no acid-fast bacilli was seen. Among malignant effusion only 61.5% of the effusion showed malignant cells on cytological examination. In other studies the percentage demonstrating malignant cells ranged from 40% to 87%.^[27] In the literature cytology has been a more sensitive test to diagnose malignancy when compared to biopsy. However in our study of pleural fluid cytology, if only one sample is sent, the yield was 60%. The yield increases with the number of samples examined and reaches a maximum with 3 samples. While this is consistent with observed literature, the numbers are too small to draw a definite conclusion.

In comparison to other studies: Follander^[20] – demonstrated predominance of lymphocytes and scarcity of mesothelial cells in tubercular effusion; Nance KV^[28] – cytology for malignancy was diagnostic in 71%; Light RW^[29] – large number of neutrophils indicate the presence of bacterial pneumonia. Lymphocytes predominant in tubercular pleural effusion. Cytology for malignant cells was positive in 33-87%; Light^[30] – demonstrated predominantly polymorphs in bacterial pneumonia.

2. Proteins : The amount of proteins in the pleural fluid ranged from 3.2 gm/dl to 6 gm/dl. The mean protein level in tuberculous effusion was 4.19 gm/dl, in malignant effusion was 3.8 gm/dl, in synpneumonic effusion was 4 gm/dl, in empyema it was 3.8 gm/dl. In study by Richard W. Light^[6] pleural protein was more than 3gm%.

3. Glucose : The glucose level in the pleural fluid ranged from 18 to 147mg%. Low glucose levels were associated with tuberculous effusions, synpneumonic, empyema. In our study, the mean values of pleural fluid glucose were: tuberculous effusion – 75.5 mg %, malignant effusion – 84 mg%, synpneumonic effusion – 57 mg %, empyema - 49 mg%. Low pleural fluid glucose was seen predominantly in patients with synpneumonic effusion and empyemas. The majority of pleural fluid glucose levels were between 40-100 mg/dl in tubercular effusions, consistent with the earlier observation by Light^[10]. 46% of our patients with malignant effusion had pleural fluid glucose level less than 40mg/dl, similar to that observed by Rodriguez-Panadero et al (20%)^[31]. Presence of low pleural fluid glucose in malignant effusion indicates a poor prognosis, as it reflects a greater tumor burden. In comparison to other studies: Antony Seaton^[1] – showed glucose level <60mg% in synpneumonic, empyema, tubercular and malignancy and >60mg% in transudates; Richard W. Light^[32] – pleural fluid glucose level below 40mg% in synpneumonic and empyema; Carr DT^[33] – in his study of glucose in pleural effusion concluded that low value is seen in exudative pleural effusion and normal in cases of transudative effusion.

4. Adenosine Deaminase levels : The mean levels of Adenosine Deaminase in the pleural fluid in the various groups of effusions were estimated. In tuberculous effusions the mean ADA level was 66 IU/L, in malignant effusion the mean ADA level was 22 IU/L. In the present study, the pleural fluid ADA values were increased in all types of effusion but the ADA values were significantly higher in tuberculous effusions (p<0.001). According to the literature pleural fluid adenosine deaminase (ADA) has got a good discriminative value in differentiating tuberculous effusions from malignant effusion. Although a pleural fluid ADA above 70IU/L is diagnostic of tuberculosis^[9] it has to be considered if the pleural fluid ADA is between 40 IU/L and 70 IU/L. An ADA level less than 40IU/L rules out pleural tuberculosis. But different authors have used different cut off levels for pleural fluid ADA ranging between 33 IU/L to 50 IU/L.^[34,35,36,37,38]. In our study out of 67 patients with

tubercular pleural fluid, ADA was done in all of them and 33 (49%) of them had a level more than 40IU/L but 22 % showed a level of less than 30IU/L. Though studies done in the West demonstrate pleural fluid ADA more than 70 IU/L (Valdes et al^[39] and Burgess et al^[40]), our study showed a mean of 66 IU/L. But a significant percent of patients had a pleural fluid ADA less than 30IU/L. The mean ADA were high in the 2 Indian studies done by Rajendra Prasad et al^[41], and Gilhotra et al^[42] with the mean ADA level ranging between 76.8 IU (+/-23.8) to 95.8 (+/-57.5). In comparison to other studies: Lesley J. Burgess^[12], M.F. Baganha^[21] and R.K. Chopra^[22] Values >45 IU/L is a sensitive method to differentiate tuberculous from non-tuberculous effusion.

5. Lactate dehydrogenase : The average LDH value in tubercular effusion – 251, malignant - 346, synpneumonic - 513 and empyema - 1244. The mean LDH in exudate effusion was higher. In comparison to other studies: Lakhota^[32] – pleural fluid LDH >200 U/L and pleural fluid to serum ratio >0.6 helps to classify the effusion as transudates. The same view was held by Marina Costa^[35].

Thus, the first step in the evaluation of a pleural effusion is to identify the cause of the effusion. This is achieved by a detailed history, clinical examination, relevant blood tests, radiological features and analysis of the pleural fluid for cytology, bacteriology and biochemical parameters like protein, glucose, L.D.H. and ADA. This is important because in case of transudates, therapy is directed towards the underlying disease like congestive cardiac failure, nephrotic syndrome, liver cirrhosis or hypoproteinemia and usually therapeutic measures directed at the pleura are not necessary. But in case with exudate effusion, a definitive diagnosis has to be established, specific therapy for the pleural disease must be instituted.

REFERENCES

- Light RW. Anatomy of pleura pleural disease. Pleural diseases. 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2013. Richard W. Light.
- Pleural effusion *N Engl J Med* 2002; 346:1971-1977
- Maldhure, Bedharkar kulkarni et al. Pleural biopsy and adenosine deaminase in the pleural fluid in the diagnosis of tubercular pleural effusion. *Ind J Tuberculosis* 1994; 41:161-164
- Park. Text book of preventive and social medicine. Epidemiology of Tuberculosis. 23rd edition 2005, Bansaril publications. Text book of preventive and social medicine. Epidemiology of Tuberculosis. 18th edition 2005, Bansaril publications.
- Light RW. Establishing the diagnosis of tuberculous pleuritis. *Arch Intern Med* 1998; 158:1967-1968.
- Aoki Y, Katoh O, Nakanishi Y et al. A comparison of study of gamma interferon, ADA, and CA 125 as the diagnostic parameters in tuberculous pleuritis. *Respir Med* 1994;88:139-143
- McKenna JM, Chandrasekar AJ, Henkin RE et al. Diagnostic value of CEA in exudative effusions. *Chest* 1980;78:587-590.
- Alfageme I, Munoz F, Pena N et al. Empyema of the thorax in adults Etiology, microbiology and management. *Chest* 1993; 103: 1502-1507
- Storm HKR, Krasnik M, Bang K, et al. Treatment of pleural empyema secondary to pneumonia: thoracocentesis regimen versus tube drainage. *Thorax* 1992; 47:77-81.
- Poe RH, Matthew GM, Israel RH, et al. Utility of decortication in Parapneumonic effusions. *Chest* 1991; 100:963-967.
- Valdes L, Alvarez D, San Jose E et al. Tuberculous pleurisy: a study of 254 patients. *Arch Intern Med* 1998; 158:2017-2021
- Berger HW, Mejia E. Tuberculous pleurisy. *Chest* 1973; 63:88-92.
- Epstein DM, Kline LR, Albelda SM, et al. Tuberculous pleural effusions. *Chest* 1987; 91:106-109.
- Aho K, Brander E, Patiala J. Studies for primary drug resistance in tuberculous pleurisy. *Scand J Respir Dis* 1968; 63:[Suppl]:111-114
- Pathak AK, Bhutan M, Mohan A et al. Non small cell lung cancer, current status and future prospects Indian J of Chest Dis and Allied Sci 2004;46:191-203
- Maria Virginia Villegas, Luz Angela Labrada et al. Evaluation of Polymerase chain reaction, Adenosine deaminase, and gamma interferon in the pleural fluid for the differential diagnosis of pleural tuberculosis. *Chest* 2000; 118: 1355-1364
- Maher GG, Berger JW et al. Massive pleural effusions and non malignant causes in 46 patients. *Am Rev Resp Dis* 1972; 105:458-460
- Bartlett JG. Gorbach SL, Thadepalli H, et al. Bacteriology of empyema. *Lancet* 1974; 1:338-340. Varkey B, Rose HD, Kutty CPK, et al. Empyema thoracis during a ten-year period. *Arch Intern Med* 1981; 141:1771-1776
- Fujiwara H, Tsuyuguchi I. Frequency of tuberculin reactive T-lymphocytes in pleural fluid and blood from patients with tuberculous pleurisy. *Am Rev Resp Dis* 1986; 89:530-532
- Shimokata K, Kawachi H, Kishimoto H, et al. Local cellular immunity in tuberculous pleurisy. *Am Rev Respir Dis* 1982; 128:822-824.
- Bueno CE, ClementeG, Castro BC, et al. Cytologic and bacteriologic analysis of fluid and pleural biopsy specimens with Cope's needle *Arch Intern Med* 1990; 150:1190-1194
- Burgess LJ, Maritz FJ, Le Roux I, et al. Use of adenosine deaminase as a diagnostic tool for tuberculous pleurisy. *Thorax* 1995; 50:672-674
- Roth B J, O'Meara TF, Cragun WH. The serum effusion albumin gradient in the evaluation of pleural effusions *Chest* 1990; 98:546-549.
- Spriggs AI, Boddington MM. *The cytology of effusions*. 2nd Edition New York: Grune & Stratton, 1968
- Dekker A, Bupp PA, et al. Cytology of serous effusions. An investigation into The

- usefulness of cellblocks versus smears. *Am J Clinical Path* 1978; 70: 855-860
26. Brook I, Frazier EH. Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. *Chest* 1993; 103:1502-1507
 27. Andrews NC, Parker EF, Shaw RR, et al. Management of non tuberculous empyema. *Am Rev Respir Dis* 1962; 85:935-936.
 28. Johnston WW. The malignant pleural effusion: a review of Cytopathological diagnosis of 584 specimens from 472 consecutive patients. *Cancer* 1985; 56:905-909.
 29. Dodson WH, Hollingsworth JW. Pleural effusion in rheumatoid arthritis. *N Engl J Med* 1966; 275:1337-1342.
 30. Perez-Rodriguez E, Castro DJ. The use of ADA isoenzymes analysis in pleural effusions: diagnostic role and relevance to the origin of increased in tuberculous pleurisy. *Curr Opin* 2000; 6: 259-266.
 31. Leong SS, Lima CM, Sherman CA, et al. The 1997 International staging system for non- small cell lung cancer: have all the issues been addressed? *Chest* 1999; 115:242-248
 32. Victoria Villena, Angela Lopez, Francisco Pozo et al. Interferon gamma levels in the pleural fluid in the diagnosis of tuberculosis *The Am J Med* 2003; 115: 365-370
 33. Villena V, Lopez E, et al. Gamma interferon in 388 immunocompromised and immunocompetent patients for the diagnosis of pleural tuberculosis. *Euro Resp J* 1996; 9: 2635-2639.
 34. Yash P. Kataria, Imtiaz Kurshid. ADA in the diagnosis of pleural tuberculosis. *Chest* 2001; 120:334-336
 35. Manuel Fontes, Alice Pego et al. Serum and pleural ADA, Correlation with Lymphocytic population. *Chest* 1990; 97:605-610
 36. Rajendra Prasad, Tripathi, Mukerji et al. Adenosine deaminase activity in pleural fluid *Indian J Chest Dis Allied Sci* 1992; 34:123-126
 37. Perez-Rodriguez E, Castro DJ. The use of ADA isoenzymes analysis in pleural effusions: diagnostic role and relevance to the origin of increased in tuberculous pleurisy. *Curr Opin* 2000; 6: 259-266
 38. Gilhotra R, Seghal, S, Gindal SK et al. Pleural biopsy and adenosine deaminase activity in effusions of different etiologies. *Lung India* 1989; 3:122-124
 39. Raj B, Chopra RK, Lal H, et al. Adenosine deaminase activity in pleural fluid: A diagnostic aid in tuberculous pleural effusion. *Indian J Chest Dis Allied Sci* 1985; 26:27
 40. Pranay kumar S, Sinha BB, Akhouri et al. Diagnosing tuberculous pleural effusion: sensitivity of mycobacterial culture, histopathology and adenosine deaminase activity. *J of Assoc of Phy of India* 1985; 33:644-645
 41. Conde MB, Loivos AC, Rezende VM, et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. *Am J Respir Crit Care Med*. 2003; 167:72
 42. Amit B, Khilani GC, Sharma SK et al. A study of empyema thoracis and the role of intrapleural streptokinase in its management. *BMC infectious diseases* 2004; 4:19-23.